S-1: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is undertaking a public offering of up to 1,557,632 shares of common stock along with common warrants to purchase up to 3,115,264 shares.
• The offering also includes pre-funded warrants for purchasers who would exceed beneficial ownership limits, exercisable for common stock at $0.0001 per share.
• Each share of common stock or pre-funded warrant is offered with two common warrants.
• The assumed combined public offering price is $3.21 per share and common warrant, based on the closing price on February 24, 2025, but the actual price will be determined by market conditions.
• The common warrants' exercise price is to be determined, and they will be exercisable upon stockholder approval or immediately if certain pricing conditions are met, expiring five years from the initial exercise date.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering, which is expected to close no later than April 15, 2025.
• The company intends to use the net proceeds of approximately $4.4 million for working capital and general corporate purposes, including the further development of its product candidates.

Sentiment

Score: 5

Explanation: Neutral sentiment. The announcement is a standard capital raising activity. While it provides funds for the company, it also introduces dilution for existing shareholders.

Positives

• The offering provides Aptevo with additional capital to fund its clinical programs and general corporate purposes.
• The inclusion of pre-funded warrants allows the company to accommodate investors who might otherwise be restricted by ownership limits.
• The engagement of Roth Capital Partners, LLC as placement agent brings expertise in arranging such offerings.

Negatives

• The offering may cause immediate and substantial dilution in the net tangible book value per share of the common stock.
• There is no guarantee that the company will obtain stockholder approval for the common warrants to be exercisable.
• There is no established public trading market for the common warrants or pre-funded warrants, and the company does not expect a market to develop.
• The offering is a reasonable best efforts offering, and there is no guarantee that the company will raise the amount of capital it believes is required for its business plans.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
• The common warrants are not exercisable until Stockholder Approval and may not have any value.
• The common warrants and pre-funded warrants are speculative in nature.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans.

Future Outlook

The company intends to use the net proceeds from this offering for working capital to fund its clinical programs and general corporate purposes, including the further development of its product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Sixteen new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Shareholders will experience potential dilution.
• The company will have additional capital to fund its operations and development programs.
• Potential investors have the opportunity to invest in Aptevo Therapeutics.

Next Steps

• The company will seek stockholder approval for the common warrants to be exercisable.
• The company will file a Prospectus Supplement with the Commission.
• The company will apply to list the Shares and Warrant Shares on the Nasdaq Capital Market.
• The company will close the offering, expected no later than April 15, 2025.

Key Dates